Automate Your Wheel Strategy on SPRC
With Tiblio's Option Bot, you can configure your own wheel strategy including SPRC - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol SPRC
- Rev/Share 0.645
- Book/Share 4.415
- PB 1.4998
- Debt/Equity 0.0056
- CurrentRatio 5.3631
- ROIC -0.8127
- MktCap 3114635.0
- FreeCF/Share -2.5209
- PFCF -0.6102
- PE -1.9461
- Debt/Assets 0.0044
- DivYield 0
- ROE -0.8338
- Rating C
- Score 2
- Recommendation Sell
- P/E Score 1
- DCF Score 1
- P/B Score 3
- D/E Score 4
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| No ratings available. | |||||||
News
SciSparc: AutoMax's Shareholders Approve Merger with SciSparc
Published: August 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, Aug. 28, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that AutoMax Motors Ltd. ("AutoMax"), a leading parallel vehicle importer in Israel, convened today its special general meetings, at which, among others, AutoMax's shareholders voted on and approved the proposed merger with SciSparc. In addition, on August 26, 2025, SciSparc's shareholders voted on and approved at an adjourned special general meeting, among others, the proposed merger.
Read More
SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Combination Therapy Targeting Weight Loss and Fatty Liver Disease
Published: July 30, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) ("Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, announced today that its collaboration with Clearmind Medicine Inc. (Nasdaq: CMND) (“Clearmind”) has led to the filing of a new international patent application under the Patent Cooperation Treaty. The application covers its innovative combination therapy of 5-methoxy-2-aminoindane and N-Acylethanolamines (MEAI) and Palmitoylethanolamide (PEA).
Read More
SciSparc Extends $2 Million Loan to Support AutoMax's Growth Following AutoMax's Entry into Direct Import of JAC Electric Vehicles
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral
TEL AVIV, Israel, Feb. 27, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the "Company" or "SciSparc"), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announced today that it has entered into a loan agreement with AutoMax Motors Ltd. ("AutoMax") to provide a $2 million loan (the “New Loan”). The funding will support AutoMax's business expansion following its entry into the direct import of Anhui Jianghuai Automobile Group Corp., Ltd. (“JAC”) electric vehicles. The New Loan is in addition to previous bridge loans in an aggregate amount of $4.25 …
Read More
About SciSparc Ltd. (SPRC)
- IPO Date 2021-08-30
- Website https://scisparc.com
- Industry Biotechnology
- CEO Oz Adler CPA
- Employees 2